Amex Biotechnology Index (BTK)

FierceBiotech  Mar 8  Comment 
A phase 2a trial of Merck KGaA’s BTK inhibitor evobrutinib has hit its primary endpoint. The prospect chalked up the win by reducing gadolinium-enhancing T1 lesions by more than placebo, but Merck has yet to quantify the difference or say how it...
GenEng News  Nov 9  Comment 
Sanofi will develop Principia Biopharma’s Phase I central nervous system (CNS) candidate PRN2246 as a treatment for multiple sclerosis (MS), through a collaboration that could generate up to $805 million for Principia, the companies said today....
MedPage Today  Oct 31  Comment 
(MedPage Today) -- Preliminary study showed 81% response rate with BTK inhibitor  Dec 13  Comment 
MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or Refractory CLL or SLL Previously Treated with a BTK Inhibitor MorphoSys AG / MorphoSys Starts Phase 2 Trial of MOR208 in Combination with...
MedPage Today  Dec 9  Comment 
(MedPage Today) -- Acalabrutinib leads to 95% overall response rate in preliminary trial
Clusterstock  Mar 27  Comment 
Credit Suisse analysts say biotechs are not in a bubble. Still, in a note Friday, the firm presents  evidence for the industry being in in a bubble, and other evidence that it definitely isn't. The signs that there’s a bubble, they...
GenEng News  Mar 19  Comment 
Eli Lilly will join in developing and commercializing Hanmi Pharmaceutical's Phase I compound HM71224 for autoimmune and other diseases, in a deal that could generate up to $690 million, plus royalties, for Hanmi. HM71224 is an oral Bruton's...
MedPage Today  Dec 11  Comment 
(MedPage Today) -- Responses, stable disease increase across range of doses.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki